Skip header and navigation

Refine By

   MORE

35 records – page 1 of 4.

Acute and continuation therapy in unipolar depression: observations from the run-in phase of a maintenance trial.

https://arctichealth.org/en/permalink/ahliterature93367
Source
Acta Psychiatr Scand. 2008 Aug;118(2):123-9
Publication Type
Article
Date
Aug-2008
Author
Gram L F
Author Affiliation
Clinical Pharmacology, IST, University of Southern Denmark, Winsløwparken 19, DK-5000 Odense C, Denmark. lf_gram@yahoo.com
Source
Acta Psychiatr Scand. 2008 Aug;118(2):123-9
Date
Aug-2008
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antidepressive Agents - therapeutic use
Denmark
Depressive Disorder - drug therapy - psychology - therapy
Electroconvulsive Therapy
Female
Follow-Up Studies
Humans
Male
Mental Disorders - drug therapy - psychology
Middle Aged
Psychiatric Status Rating Scales - statistics & numerical data
Psychotropic Drugs - therapeutic use
Recurrence
Severity of Illness Index
Time
Treatment Outcome
Abstract
OBJECTIVE: The aim of the study was to analyze treatments and outcome in depressed patients. METHOD: Patients with recurrent depressive disorder (n = 289), recruited for a prophylaxis study, were followed up in hospital settings for 6 months with diagnostic and depression ratings at baseline and monthly depression ratings. Data on psychotropic drugs were retrieved from hospital case records. Independent associations between baseline, treatment and outcome variables were examined by logistic regression models. RESULTS: Depressive symptoms subsided gradually. After 6 months, 21% had dropped out, 43% were rated as remitted (HAM-D-17 15). Patients once remitted rarely relapsed (
PubMed ID
18384466 View in PubMed
Less detail

Adaptive and non-adaptive models of depression: A comparison using register data on antidepressant medication during divorce.

https://arctichealth.org/en/permalink/ahliterature286094
Source
PLoS One. 2017;12(6):e0179495
Publication Type
Article
Date
2017
Author
Tom Rosenström
Tim W Fawcett
Andrew D Higginson
Niina Metsä-Simola
Edward H Hagen
Alasdair I Houston
Pekka Martikainen
Source
PLoS One. 2017;12(6):e0179495
Date
2017
Language
English
Publication Type
Article
Keywords
Adaptation, Psychological
Adult
Algorithms
Antidepressive Agents - therapeutic use
Depressive Disorder - drug therapy - psychology
Divorce - psychology
Drug Therapy - statistics & numerical data
Female
Finland
Humans
Male
Middle Aged
Models, Psychological
Registries - statistics & numerical data
Young Adult
Abstract
Divorce is associated with an increased probability of a depressive episode, but the causation of events remains unclear. Adaptive models of depression propose that depression is a social strategy in part, whereas non-adaptive models tend to propose a diathesis-stress mechanism. We compare an adaptive evolutionary model of depression to three alternative non-adaptive models with respect to their ability to explain the temporal pattern of depression around the time of divorce. Register-based data (304,112 individuals drawn from a random sample of 11% of Finnish people) on antidepressant purchases is used as a proxy for depression. This proxy affords an unprecedented temporal resolution (a 3-monthly prevalence estimates over 10 years) without any bias from non-compliance, and it can be linked with underlying episodes via a statistical model. The evolutionary-adaptation model (all time periods with risk of divorce are depressogenic) was the best quantitative description of the data. The non-adaptive stress-relief model (period before divorce is depressogenic and period afterwards is not) provided the second best quantitative description of the data. The peak-stress model (periods before and after divorce can be depressogenic) fit the data less well, and the stress-induction model (period following divorce is depressogenic and the preceding period is not) did not fit the data at all. The evolutionary model was the most detailed mechanistic description of the divorce-depression link among the models, and the best fit in terms of predicted curvature; thus, it offers most rigorous hypotheses for further study. The stress-relief model also fit very well and was the best model in a sensitivity analysis, encouraging development of more mechanistic models for that hypothesis.
Notes
Cites: Am J Psychiatry. 2007 Oct;164(10):1521-9; quiz 162217898343
Cites: Psychol Methods. 2012 Jun;17(2):228-4322309957
Cites: J Affect Disord. 2017 Jan 1;207 :38-4627690352
Cites: Arch Gen Psychiatry. 2009 Aug;66(8):848-5619652124
Cites: Int J Epidemiol. 2015 Apr;44(2):566-7726054357
Cites: Psychol Rev. 2009 Jul;116(3):620-5419618990
Cites: J Affect Disord. 2016 Jan 15;190:632-926590510
Cites: Annu Rev Clin Psychol. 2010;6:285-31220192795
Cites: Psychol Med. 2015 Jul;45(9):1945-5425781917
Cites: Eur J Clin Pharmacol. 2015 Mar;71(3):369-7525560052
Cites: Psychol Med. 2013 Apr;43(4):711-922687325
Cites: J Pers Soc Psychol. 1987 Jun;52(6):1274-823598866
Cites: J Clin Psychiatry. 2016 Feb;77(2):252-6026797163
Cites: Am Psychol. 1992 Mar;47(3):373-881562108
Cites: Psychol Bull. 2014 May;140(3):774-81524417575
Cites: Am J Psychiatry. 2016 Aug 1;173(8):771-8027138588
Cites: Evol Med Public Health. 2015 Apr 26;2015(1):123-3525916884
Cites: Am J Psychiatry. 1995 Jun;152(6):833-427755111
Cites: Arch Suicide Res. 2015;19(4):414-2126452767
Cites: Pharmacoepidemiol Drug Saf. 2012 Sep;21(9):980-822511574
Cites: Ann Epidemiol. 1997 Apr;7(3):213-89141645
Cites: Mol Psychiatry. 2012 Dec;17(12):1174-922869033
Cites: Am J Psychiatry. 2011 Mar;168(3):257-6421245088
Cites: JAMA Psychiatry. 2013 Jun;70(6):599-60723740048
Cites: Soc Sci Med. 2013 Oct;94:71-8023931947
Cites: Acta Psychiatr Scand. 2009 Nov;120(5):386-9119807720
Cites: Am J Psychiatry. 2000 Dec;157(12):1925-3211097952
Cites: Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):746-5217286318
Cites: Psychol Assess. 2016 Nov;28(11):1354-136726821198
Cites: World Psychiatry. 2015 Oct;14(3):294-30026407778
Cites: J Affect Disord. 2013 Jun;148(2-3):278-8523357655
Cites: Depress Anxiety. 2009;26(12):1172-719798680
Cites: Addiction. 2012 May;107(5):900-821992148
Cites: J Affect Disord. 2002 Dec;72(3):227-3612450639
Cites: Psychol Rev. 1992 Apr;99(2):232-471594724
Cites: Proc R Soc Med. 1965 May;58:295-30014283879
Cites: Int J Epidemiol. 2015 Apr;44(2):526-3925433705
Cites: World Psychiatry. 2014 Jun;13(2):153-6024890068
Cites: Arch Gen Psychiatry. 2006 Oct;63(10):1113-2017015813
Cites: Psychol Bull. 2003 Nov;129(6):887-91314599287
Cites: J Abnorm Psychol. 2016 Jul;125(5):727-4527254487
Cites: World Psychiatry. 2017 Feb;16(1):5-1328127906
Cites: J Nerv Ment Dis. 1998 Nov;186(11):661-99824167
Cites: Physiol Rev. 2015 Jul;95(3):853-95126109341
Cites: Popul Stud (Camb). 2012 Mar;66(1):69-8522239474
Cites: Lancet. 2012 Dec 15;380(9859):2071-9423245603
Cites: Psychol Sci. 2001 Sep;12(5):371-811554669
Cites: Am J Psychiatry. 2010 Jul;167(7):801-820478879
Cites: J Pers Disord. 2012 Jun;26(3):334-4422686222
Cites: World Psychiatry. 2013 Feb;12(1):44-5223471801
Cites: Can J Psychiatry. 2011 Dec;56(12):716-2622152640
Cites: Lancet. 2013 Nov 9;382(9904):1575-8623993280
Cites: Evol Med Public Health. 2016 Feb 28;2016(1):52-6626929090
Cites: Psychol Med. 2010 Sep;40(9):1475-8419917148
Cites: J Affect Disord. 2004 Apr;79(1-3):1-1115023475
Cites: J Theor Biol. 1997 Nov 21;189(2):211-259405138
Cites: Clin Psychol Sci. 2016 Mar;4(2):229-23827034912
Cites: BMC Psychiatry. 2017 Jan 23;17 (1):3928114985
Cites: BMC Med. 2011 Jul 26;9:9021791035
Cites: JAMA Psychiatry. 2013 Jan;70(1):22-3023147713
Cites: Psychol Bull. 1991 Nov;110(3):406-251758917
Cites: Psychol Bull. 1995 May;117(3):363-867777644
Cites: Evol Med Public Health. 2016 Mar 23;2016(1):117-3226884416
Cites: J Affect Disord. 2015 Feb 1;172:315-2325451432
Cites: Proc Natl Acad Sci U S A. 2011 Sep 13;108 Suppl 3:15647-5421389268
Cites: Psychiatr Serv. 2014 Jul;65(7):944-624788368
Cites: Int J Methods Psychiatr Res. 2015 Sep;24(3):213-2526140369
Cites: J Affect Disord. 2014 Apr;158:139-4724655778
Cites: Acta Psychiatr Scand. 2009 Apr;119(4):312-919077132
Cites: Am Psychol. 1998 Feb;53(2):221-419491749
Cites: JAMA Psychiatry. 2016 Jun 1;73(6):575-8127097014
Cites: J Affect Disord. 2002 Oct;72(1):1-1412204312
Cites: J Consult Clin Psychol. 1987 Jun;55(3):341-63597946
Cites: J Theor Biol. 2013 Aug 21;331:54-6523608629
Cites: Br J Psychiatry. 2009 Aug;195(2):118-2519648541
Cites: Annu Rev Clin Psychol. 2014;10:393-42324471371
PubMed ID
28614385 View in PubMed
Less detail

Adverse experiences during treatment with zimeldine on special licence in Sweden.

https://arctichealth.org/en/permalink/ahliterature46553
Source
Int Clin Psychopharmacol. 1994;9(1):55-61
Publication Type
Article
Date
1994
Author
B O Bengtsson
B E Wiholm
M. Myrhed
J. Wålinder
Author Affiliation
Department of Psychiatry, Faculty of Health Sciences, University Hospital, Linköping, Sweden.
Source
Int Clin Psychopharmacol. 1994;9(1):55-61
Date
1994
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Depressive Disorder - drug therapy - psychology
Drug Approval - legislation & jurisprudence
Drug Hypersensitivity - etiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neurologic Examination - drug effects
Zimeldine - adverse effects - therapeutic use
Abstract
Adverse experiences during licensed treatment with the antidepressant serotonin (5-HT) reuptake inhibitor zimeldine in Sweden are presented. Data were obtained from a written inquiry of 694 patients and 67 reports to the Medical Products Agency. The spectrum of adverse symptoms was in agreement with those reported in previous studies on zimeldine. The most frequent adverse experiences were headache, nausea, myalgia, signs of liver function disturbance, arthralgia, neurological symptoms, fever and insomnia. No new case of the Guillain-Barré syndrome was found. The estimated frequency of the zimeldine-induced hypersensitivity syndrome (HSS), comprising fever, myalgia and/or arthralgia and signs of liver function disturbance, ranged from 1.4% to 13% in the inquiry and from 0.63% to 3.4% in the report part of the study. Adverse experiences usually had a considerably higher incidence during the first 6 weeks of zimeldine treatment than thereafter. This is in agreement with the clinical experience that most of the adverse reactions occur early during zimeldine treatment. However, a number of adverse experiences did occur with a later onset. This may justify a prolongation of the compulsory 4 weeks' testing of liver function that is required during licensed treatment. There were significantly fewer patients who developed fever among the patients who had experienced previous zimeldine treatment than among those who had not. Otherwise there was no statistically significant difference in frequency of adverse symptoms between these two groups. Consequently zimeldine treatment per se does not seem to predispose to development of an HSS or other types of adverse reactions during subsequent therapy.
PubMed ID
8195584 View in PubMed
Less detail

Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

https://arctichealth.org/en/permalink/ahliterature198452
Source
J Clin Psychiatry. 2000 Apr;61(4):276-81
Publication Type
Article
Date
Apr-2000
Author
S H Kennedy
B S Eisfeld
S E Dickens
J R Bacchiochi
R M Bagby
Author Affiliation
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada. sidney_kennedy@camh.net
Source
J Clin Psychiatry. 2000 Apr;61(4):276-81
Date
Apr-2000
Language
English
Publication Type
Article
Keywords
Adult
Cyclohexanols - adverse effects - therapeutic use
Depressive Disorder - drug therapy - psychology
Female
Humans
Libido - drug effects
Male
Middle Aged
Moclobemide - adverse effects - therapeutic use
Monoamine Oxidase Inhibitors - adverse effects - therapeutic use
Ontario - epidemiology
Orgasm - drug effects
Paroxetine - adverse effects - therapeutic use
Prevalence
Psychiatric Status Rating Scales - statistics & numerical data
Serotonin Uptake Inhibitors - adverse effects - therapeutic use
Sertraline - adverse effects - therapeutic use
Sex Factors
Sexual Dysfunctions, Psychological - chemically induced - diagnosis - epidemiology
Treatment Outcome
Abstract
Recent reports suggest that adverse effects on sexual function occur in up to 50% of patients who are treated with selective serotonin reuptake inhibitor (SSRI) antidepressants. Previously cited low rates were more likely a function of underreporting than underoccurrence. There is less evidence about rates of dysfunction with serotonin-norepinephrine reuptake inhibitor (SNRI) and reversible inhibitor of monoamine oxidase A (RIMA) antidepressants. The purpose of this report is to evaluate disturbances in sexual drive/desire and arousal/orgasm in 107 patients who met criteria for major depressive disorder and received treatment with either moclobemide, paroxetine, sertraline, or venlafaxine.
All consenting eligible patients who met DSM-IV criteria for major depressive disorder completed the Sexual Functioning Questionnaire, version 1 (SFQ) and were assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D) prior to and after 8 or 14 weeks of antidepressant therapy. Analyses were carried out to examine the effect of gender, drug type, pretreatment level of sexual dysfunction, and drug response on reported sexual dysfunction.
Compared with women, men experienced a significantly greater level of drug-related impairment in drive/desire (p
PubMed ID
10830148 View in PubMed
Less detail

Antidepressants to cancer patients during the last year of life--a population-based study.

https://arctichealth.org/en/permalink/ahliterature126418
Source
Psychooncology. 2013 Mar;22(3):506-14
Publication Type
Article
Date
Mar-2013
Author
Siri Brelin
Jon Håvard Loge
Svetlana Skurtveit
Tom Børge Johannesen
Nina Aass
Stig Ottesen
Marianne Jensen Hjermstad
Author Affiliation
Oslo University Hospital, Regional Centre for Excellence in Palliative Care, Department of Oncology, Oslo, Norway. siri.brelin@gmail.com
Source
Psychooncology. 2013 Mar;22(3):506-14
Date
Mar-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antidepressive Agents - therapeutic use
Cohort Studies
Databases, Factual
Depressive Disorder - drug therapy - psychology
Female
Humans
Male
Middle Aged
Neoplasms - psychology
Norway
Palliative Care - statistics & numerical data
Physician's Practice Patterns - statistics & numerical data
Retrospective Studies
Young Adult
Abstract
Although depression is common among incurable cancer patients, the prescription prevalence of antidepressants (ADs) to these patients is largely unknown. Aims were to examine the prescription prevalence of ADs in the last year of life in a 2-year national cancer death cohort and to examine its associations with sociodemographic and medical variables.
Nationwide, 20,627 cancer deaths in adults were identified by combining the Norwegian Central Population and Cancer Registries. Individual prescriptions of ADs in the 12 months prior to death were identified in the Norwegian Prescription Database. The study population consisted of 17,753 patients who died from cancer in 2005 and 2006, after excluding patients assumed to be hospitalized whose prescriptions were not registered in the Norwegian Prescription Database.
Twenty-two percent (N = 3836) had at least one prescription of ADs in their last year of life (men 19%/women 25%), compared with 6% in the general population (men 4%/women 8%). Patients who died within 1 year from diagnosis had lower prescription prevalence (20%) than patients with longer disease duration (23%) (p
PubMed ID
22392773 View in PubMed
Less detail

Antidepressant treatment among social workers, human service professionals, and non-human service professionals: A multi-cohort study in Finland, Sweden and Denmark.

https://arctichealth.org/en/permalink/ahliterature301926
Source
J Affect Disord. 2019 05 01; 250:153-162
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
05-01-2019
Author
O Rantonen
K Alexanderson
A J Clark
V Aalto
A Sónden
H Brønnum-Hansen
C Ø Hougaard
N H Rod
E Mittendorfer-Rutz
M Kivimäki
T Oksanen
P Salo
Author Affiliation
Finnish Institute of Occupational Health, Helsinki, Finland; Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Psychology, University of Turku, Turku, Finland. Electronic address: optran@utu.fi.
Source
J Affect Disord. 2019 05 01; 250:153-162
Date
05-01-2019
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Antidepressive Agents - therapeutic use
Cohort Studies
Denmark
Depressive Disorder - drug therapy - psychology
Female
Finland
Health Personnel - psychology
Humans
Male
Middle Aged
Prospective Studies
Registries
Social Workers - psychology
Sweden
Abstract
Social workers have an elevated risk for mental disorders, but little is known about their antidepressant treatment.
To examine any and long-term antidepressant treatment among social workers in Finland, Sweden and Denmark.
We linked records from drug prescription registers to three prospective cohorts: the Finnish Public Sector study, years 2006-2011, and nation-wide cohorts in Sweden and Denmark, years 2006-2014, including a total of 1.5 million employees in (1) social work, (2) other social and health care professions, (3) education and (4) office work. We used Cox proportional hazards models to estimate hazard ratios for any and long-term (>6 months) antidepressant treatment among social workers compared to the three reference occupational groups and carried out meta-analyses.
During follow-up, 25% of social workers had any prescriptions for antidepressants (19-24% reference occupations) and 20% for long-term treatment (14-19% reference occupations). The pooled effects for any and long-term treatment showed that probabilities were 10% higher in social workers compared to other health and social care professionals and 30% higher compared to education and non-human service professionals. Probabilities for any treatment in the three countries were relatively similar, but for long-term treatment social workers in Finland had a greater risk compared with other human service professions.
There were differences between the cohorts in the availability of data. Specific diagnoses for the antidepressant treatment were not known neither adherence to treatment.
Social workers have a higher risk for any and long-term antidepressant treatment than other human and non-human service professionals.
PubMed ID
30856492 View in PubMed
Less detail

Are the monamine oxidase inhibitors facing extinction?

https://arctichealth.org/en/permalink/ahliterature226551
Source
Can J Psychiatry. 1991 Apr;36(3):186-9
Publication Type
Article
Date
Apr-1991
Author
R L O'Reilly
Author Affiliation
St. Thomas Psychiatric Hospital, Ontario.
Source
Can J Psychiatry. 1991 Apr;36(3):186-9
Date
Apr-1991
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Antidepressive Agents - therapeutic use
Antidepressive Agents, Tricyclic - therapeutic use
Child
Depressive Disorder - drug therapy - psychology
Drug Prescriptions - statistics & numerical data
Drug Utilization - trends
Humans
Longitudinal Studies
Middle Aged
Monoamine Oxidase Inhibitors - therapeutic use
Saskatchewan
Abstract
The use of monoamine oxidase inhibitors (MAOIs) in the province of Saskatchewan was compared for two years, 1978 and 1986, using the Saskatchewan Prescription Drug Plan data base. The percentage of the adult population receiving an MAOI decreased from 0.17% in 1978 to 0.07% in 1986. The use of both tricyclic antidepressants and the new generation antidepressants increased during the same period. Physicians appear to have selectively avoided using MAOIs for the elderly. Physicians who are not psychiatrists showed the greatest reduction in their use of the MAOIs. The data indicate an increasing reluctance to prescribe the MAOIs despite the recent resurgence of interest in these agents and the positive literature concerning their safety and efficacy.
PubMed ID
2059937 View in PubMed
Less detail

Balancing Risk: A Grounded Theory Study of Pregnant Women's Decisions to (Dis)Continue Antidepressant Therapy.

https://arctichealth.org/en/permalink/ahliterature279666
Source
Issues Ment Health Nurs. 2015 Jul;36(7):485-92
Publication Type
Article
Date
Jul-2015
Author
Lene Nygaard
Camilla Blach Rossen
Niels Buus
Source
Issues Ment Health Nurs. 2015 Jul;36(7):485-92
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Adult
Antidepressive Agents - therapeutic use
Decision Making
Denmark
Depressive Disorder - drug therapy - psychology
Female
Grounded Theory
Humans
Medication Adherence - psychology
Pregnancy
Pregnancy Complications - drug therapy - psychology
Treatment Refusal - psychology
Young Adult
Abstract
This study explored how eight pregnant women diagnosed with depression managed the decision whether or not to take antidepressants during pregnancy. In total, 11 interviews were conducted and analysed by means of constructivist grounded theory. The major category constructed was Balancing risk, with two minor categories: Assessing depression and antidepressants and Evaluating the impact of significant others. The participants tried to make the safest decision, taking all aspects of their life into consideration. They described successful decision-making in the context of managing social norms that surround pregnancy, in a way that was acceptable to themselves, their significant others and healthcare professionals.
PubMed ID
26309167 View in PubMed
Less detail

Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.

https://arctichealth.org/en/permalink/ahliterature222218
Source
Clin Neuropharmacol. 1993;16 Suppl 2:S51-4
Publication Type
Article
Date
1993
Author
G. Chouinard
B M Saxena
N P Nair
S P Kutcher
D. Bakish
J. Bradwejn
S H Kennedy
V. Sharma
R A Remick
S A Kukha-Mohamad
Author Affiliation
Hôpital Louis-H. Lafontaine, Montreal, Quebec, Canada.
Source
Clin Neuropharmacol. 1993;16 Suppl 2:S51-4
Date
1993
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antidepressive Agents - therapeutic use
Canada
Depressive Disorder - drug therapy - psychology
Double-Blind Method
Female
Humans
Imipramine - therapeutic use
Male
Middle Aged
Monoamine Oxidase Inhibitors - therapeutic use
Phenelzine - therapeutic use
Piperidines - therapeutic use
Psychiatric Status Rating Scales
Tranylcypromine - therapeutic use
Abstract
Brofaromine is a new, reversible, and selective type-A monoamine oxidase inhibitor (MAOI) that also has serotonin reuptake inhibitory properties. Its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs. A multicenter, double-blind, placebo-controlled study including 220 patients was undertaken to evaluate the efficacy and safety of brofaromine in major depression. This study of a fixed-dose design and 6 weeks' duration found that brofaromine was significantly better than placebo on the Overall Evaluation of Efficacy, Beck self-rating scale, HAM-D Bech subscale, HAM-D total 14 items (minus the three sleep items), HAM-D depressed mood item and retardation factor, and worse than placebo on the insomnia items of HAM-D. Significantly more patients on placebo than on brofaromine did not complete the trial due to lack of efficacy. In comparative controlled studies (n = 899), brofaromine was found to be at least as efficacious as tricyclic antidepressants (imipramine) and standard MAOIs (tranylcypromine and phenelzine). Reductions of at least 50% in the HAM-D total score were seen in 58-66% of patients treated with either brofaromine or imipramine (n = 609). Brofaromine also was found to be of comparable efficacy to tranylcypromine in two clinical trials (n = 132), one of which included patients considered to have a treatment-resistant depression (n = 39). In another double-blind study that compared brofaromine (150 mg/day) to phenelzine (45 mg/day) (n = 158), there was no difference between brofaromine and phenelzine.
PubMed ID
8313397 View in PubMed
Less detail

Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.

https://arctichealth.org/en/permalink/ahliterature46547
Source
Int Clin Psychopharmacol. 1994 Mar;9 Suppl 1:41-8
Publication Type
Article
Date
Mar-1994
Author
C. Rosenberg
N. Damsbo
E. Fuglum
L V Jacobsen
S. Horsgård
Author Affiliation
H. Lundbeck A/S, Valby-Copenhagen, Denmark.
Source
Int Clin Psychopharmacol. 1994 Mar;9 Suppl 1:41-8
Date
Mar-1994
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Citalopram - administration & dosage - adverse effects
Comparative Study
Depressive Disorder - drug therapy - psychology
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Family Practice
Female
Humans
Imipramine - administration & dosage - adverse effects
Long-Term Care
Male
Middle Aged
Netherlands
Patient care team
Personality Inventory
Abstract
Two dose levels of citalopram, 10-30 mg and 20-60 mg, were compared with imipramine, 50-150 mg, in depressed patients treated in general practice. This was a multicentre study carried out in Denmark, Sweden, Norway, and Finland. The duration of treatment was 6 weeks with an optional continuation phase of a further 16 weeks. The patients were assessed by means of the Hamilton Rating Scale for Depression (HAMD), Clinical Global Impressions (CGI), and a visual analogue self-rating scale for depression. Observed and spontaneously reported adverse events were recorded. A total of 472 patients were entered into the study and 400 patients completed the 6 week trial period. A total of 297 patients completed the optional 22 week double-blind period. A clear reduction of the HAMD total scores was seen in all three treatment groups with no significant differences between groups. A reduction of the HAMD anxiety factor and sleep factor scores was also seen with no significant differences between treatments. The imipramine-treated patients showed a higher frequency of adverse events, especially the anticholinergic type, than citalopram-treated patients. Most patients entered into the continuation phase remained well.
PubMed ID
8021437 View in PubMed
Less detail

35 records – page 1 of 4.